CORT - Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated Logo

CORT - Corcept Therapeutics Incorporated

https://www.corcept.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.

52W High
$117.33
52W Low
$34.25

MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.29
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
61.93
Forward P/E (<15 better)
20.33
EV/EBITDA (<8 favorable)
67.15
EV/Revenue (<3 favorable)
9.74
P/S (TTM) (<3 favorable)
10.21
P/B (<3 favorable)
11.50
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
11.55%
Institutions (25–75% balanced)
76.03%
Shares Outstanding
105,372,000
Float
86,875,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
716,080,000
Gross Profit (TTM)
703,921,000
EPS (TTM)
1.12
Profit Margin (>10% good)
0.19%
Operating Margin (TTM) (higher better)
0.14%
ROE (TTM) (>15% strong)
0.22%
EPS YoY (Quarterly) (>10% good)
-0.09
Revenue YoY (Quarterly) (>8% good)
0.19
Momentum
Bearish momentum
Value
0.5940
Previous
0.4728
Trend
Rising
Signal Cross
No cross

As of
Sep. 12, 2025